Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Biotechnology

Healthcare
$33.11 -1.81%

-$0.61 today

Market cap
$1.94B
Beta
0.97
P/E (TTM)
13.2
EPS (TTM)
$2.52
52W Low $25.52High $40.87

Volume 0.57M

Average 0.82M

HRMY EBITDA Margin

EBITDA as a percentage of revenue.

Harmony Biosciences Holdings, Inc.NASDAQ: HRMY

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 39.2%

EBITDA Margin was 39.2% in Q2 FY2026, up 9.6 pp from a year earlier. On a trailing-twelve-month basis it was 28.8%, down 5.5 pp year over year. Over 3 fiscal years it narrowed by 4.2 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 9 analysts of 28.2% for the fiscal year ending Dec 2026, down from 29.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
39.2%+16.5 pp QoQ
Last fiscal yearDec 2025
29.4%-3.3 pp YoY
LTMJun 2026
28.8%-5.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+9.6 pp+1.3 pp-8.3 pp
1 year-3.3 pp-1.2 pp+2.1 pp
3 years-4.2 pp+0.9 pp+5.1 pp
5 years+4.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
29.4%
Year-over-year change
-3.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How HRMY compares with its peers on the latest reported figures

HRMY Competitors
EBITDA Margin for HRMY and competitors
Company Period LTM level YoY 3-year change
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 202628.8% -5.5 pp-4.2 pp
LBRXLB Pharmaceuticals Inc Common StockFY2025— ——
CMPSCOMPASS Pathways plcFY2025— ——
APMDApnimed, Inc.—— ——
NERVMinerva Neurosciences, Inc.FY2025— ——
Peer median (excluding HRMY) ———

Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue305.44M437.86M582.02M714.73M868.45M
Cost of Revenue55.52M83.48M121.24M156.82M198.34M
Gross Profit249.92M354.37M460.79M557.92M670.11M
Gross Margin81.8%80.9%79.2%78.1%77.2%
Research & Development30.37M70.89M76.06M145.83M189.59M
Selling, General & Admin132.03M163.3M192.69M221.27M272.05M
Operating Expenses162.39M234.19M268.76M367.09M461.64M
Depreciation & Amortization18.84M23.39M24.36M24.11M25.34M
EBITDA80.46M146.87M221.51M233.41M255.05M
EBITDA Margin26.3%33.5%38.1%32.7%29.4%
Operating Income87.53M120.19M192.03M190.83M208.47M
Operating Margin28.7%27.4%33.0%26.7%24.0%
Interest Income224K3.13M14.73M18.54M21.92M
Interest Expense24.19M18.8M23.76M17.5M14.65M
Other Income / Expenses(50.1M)(15.5M)(18.63M)978K6.6M
Income Before Tax37.43M104.69M173.4M191.8M215.06M
Pre-Tax Margin12.3%23.9%29.8%26.8%24.8%
Income Tax Expense2.83M(76.78M)44.54M46.31M56.38M
Net Income34.6M181.47M128.85M145.49M158.69M
Net Margin11.3%41.4%22.1%20.4%18.3%
EPS (Basic)0.603.072.172.562.76
EPS (Diluted)0.582.972.132.512.71
Weighted Avg Shares57.53M59.17M59.47M56.89M57.49M
Weighted Avg Shares (Diluted)59.21M61.1M60.37M57.87M58.54M

Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Intrinsic Alpha fair value

Locked

Current Price

$33.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.